{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:39:36Z","timestamp":1787960376130,"version":"build-2784847793"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":1726,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The Carillon Mitral Contour System has been shown to reduce mitral regurgitation and left ventricular volumes in symptomatic heart failure patients with functional mitral regurgitation. We sought to evaluate the effects of the Carillon device on quality of life and functional capacity in these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>An individual participant data meta-analysis was conducted utilizing data from REDUCE-FMR, TITAN, and TITAN II studies. The main outcomes assessed were changes from baseline in Kansas City Cardiomyopathy Questionnaire overall summary scores (KCCQ-OSS), 6 min walk test (6MWT) distance, and New York Heart Association (NYHA) classification at Months 1 and 12 after device implantation. Subgroup analyses were conducted for patients with severe functional mitral regurgitation (Grade 3 or 4). Pooled estimates were calculated using a random-effects model and are presented as weighted proportions or weighted mean differences along with 95% confidence intervals (CIs). Among 139 patients included in the analysis, Carillon device significantly improved the 6MWT distance (63.0 m; 95% CI 18.8\u2013107.2, P = 0.0056) and KCCQ-OSS score (15.1; 95% CI 5.6\u201324.7, P = 0.0022) at 1 month from baseline. These benefits were sustained at 12 months (64.1 m; 95% CI 13.2\u2013115.0, P = 0.0141, for 6MWT distance, and 12.3; 95% CI 4.7\u201319.8, P = 0.0019, for KCCQ-OSS score). More than 50% of the patients had improvements in KCCQ-OSS by \u22655 (60.4%; 95% CI 47.4\u201372.1) and 10 points (50.5%; 95% CI 34.9\u201366.0) at 12 months. Almost half of the patients experienced a \u22651 class improvement in NYHA class after implantation of the device at 1 month (67.9%; 95% CI 37.3\u201388.3) and at 12 months (48.8%; 95% CI 31.8\u201366.2). Results remained similar for KCCQ-OSS, 6MWT distance, and NYHA classification when only patients with Grade 3 or 4 mitral regurgitation were analysed. The pooled estimates of 30 day and 1 year all-cause mortality were 2.2% (95% CI 0.7\u20136.5) and 17.3% (95% CI 11.8\u201324.5), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The Carillon Mitral Contour System significantly improved patient-reported quality-of-life outcomes in heart failure patients with functional mitral regurgitation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13301","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T11:29:49Z","timestamp":1617103789000},"page":"1885-1891","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effect of Carillon Mitral Contour System on Patient-Reported Outcomes in Functional Mitral Regurgitation: An Individual Participant Data Meta-Analysis"],"prefix":"10.1093","volume":"8","author":[{"given":"Muhammad Shahzeb","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Mississippi , Jackson, MS ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Friede","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, University Medical Center G\u00f6ttingen, and German Centre for Cardiovascular Research (DZHK), partner site G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Cardiology (CVK), Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Mississippi , Jackson, MS ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"key":"2026012114025080300_ehf213301-bib-0001","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1067\/mhj.2002.123576","article-title":"Secondary mitral and tricuspid regurgitation accompanying left ventricular systolic dysfunction: is it important, and how is it treated?","volume":"144","author":"Trichon","year":"2002","journal-title":"Am Heart J"},{"key":"2026012114025080300_ehf213301-bib-0002","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cardfail.2003.12.006","article-title":"Mitral regurgitation in patients with advanced systolic heart failure","volume":"10","author":"Patel","year":"2004","journal-title":"J Card Fail"},{"key":"2026012114025080300_ehf213301-bib-0003","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/jamacardio.2017.2976","article-title":"Survival and cardiovascular outcomes of patients with secondary mitral regurgitation: a systematic review and meta-analysis","volume":"2","author":"Sannino","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026012114025080300_ehf213301-bib-0004","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/eurheartj\/ehi189","article-title":"Long-term outcome of patients with heart failure and dynamic functional mitral regurgitation","volume":"26","author":"Lancellotti","year":"2005","journal-title":"Eur Heart J"},{"key":"2026012114025080300_ehf213301-bib-0005","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/eurjhf\/hfq014","article-title":"Prognostic implications of functional mitral regurgitation according to the severity of the underlying chronic heart failure: a long-term outcome study","volume":"12","author":"Bursi","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026012114025080300_ehf213301-bib-0006","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/europace\/eur047","article-title":"Impact of cardiac resynchronization therapy on the severity of mitral regurgitation","volume":"13","author":"DiBiase","year":"2011","journal-title":"Europace"},{"key":"2026012114025080300_ehf213301-bib-0007","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"2026012114025080300_ehf213301-bib-0008","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012114025080300_ehf213301-bib-0009","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter mitral-valve repair in patients with heart failure","volume":"379","author":"Stone","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012114025080300_ehf213301-bib-0010","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","article-title":"Percutaneous repair or medical treatment for secondary mitral regurgitation","volume":"379","author":"Obadia","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012114025080300_ehf213301-bib-0011","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/eurjhf\/hfs076","article-title":"Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN trial","volume":"14","author":"Siminiak","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026012114025080300_ehf213301-bib-0012","article-title":"Coronary sinus-based percutaneous annuloplasty as treatment for functional mitral regurgitation: the TITAN II trial","volume":"3","author":"Lipiecki","year":"2016","journal-title":"OpenHeart"},{"key":"2026012114025080300_ehf213301-bib-0013","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jchf.2019.06.011","article-title":"The REDUCE FMR trial: a randomized sham-controlled study of percutaneous mitral annuloplasty in functional mitral regurgitation","volume":"7","author":"Witte","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026012114025080300_ehf213301-bib-0014","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ahj.2017.02.032","article-title":"A randomized double-blind trial of an interventional device treatment of functional mitral regurgitation in patients with symptomatic congestive heart failure\u2014trial design of the REDUCE FMR study","volume":"188","author":"Goldberg","year":"2017","journal-title":"Am Heart J"},{"key":"2026012114025080300_ehf213301-bib-0015","volume-title":"Clinical Outcome Assessments (COA) Qualification Submissions, Office of Cardiology, Hematology, Endocrinology, and Nephrology (OCHEN), Division of Cardiovascular and Nephrology (DCN), DDT COA #000084: Kansas City Cardiomyopathy Questionnaire (KCCQ)","author":"U.S. Food and Drug Administration","year":"2020"},{"key":"2026012114025080300_ehf213301-bib-0016","volume-title":"Treatment for heart failure: endpoints for drug development guidance for industry","author":"U.S. Food and Drug Administration"},{"key":"2026012114025080300_ehf213301-bib-0017","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026012114025080300_ehf213301-bib-0018","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/jamacardio.2017.3983","article-title":"Association of serial Kansas City Cardiomyopathy Questionnaire assessments with death and hospitalization in patients with heart failure with preserved and reduced ejection fraction: a secondary analysis of 2 randomized clinical trials","volume":"2","author":"Pokharel","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026012114025080300_ehf213301-bib-0019","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ahj.2004.12.010","article-title":"Monitoring clinical changes in patients with heart failure: a comparison of methods","volume":"150","author":"Spertus","year":"2005","journal-title":"Am Heart J"},{"key":"2026012114025080300_ehf213301-bib-0020","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1161\/CIRCOUTCOMES.115.001958","article-title":"Development and validation of a short version of the Kansas City Cardiomyopathy Questionnaire","volume":"8","author":"Spertus","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026012114025080300_ehf213301-bib-0021","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/ejhf.1810","article-title":"Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction","volume":"22","author":"Butler","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114025080300_ehf213301-bib-0022","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s11136-016-1267-9","article-title":"Quantifying clinical change: discrepancies between patients' and providers' perspectives","volume":"25","author":"Dreyer","year":"2016","journal-title":"Qual Life Res"},{"key":"2026012114025080300_ehf213301-bib-0023","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1161\/CIRCHEARTFAILURE.113.000359","article-title":"Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction","volume":"6","author":"Joseph","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026012114025080300_ehf213301-bib-0024","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jacc.2005.11.021","article-title":"Health status identifies heart failure outpatients at risk for hospitalization or death","volume":"47","author":"Heidenreich","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026012114025080300_ehf213301-bib-0025","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation"},{"key":"2026012114025080300_ehf213301-bib-0026","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation"},{"key":"2026012114025080300_ehf213301-bib-0027","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/eurheartj\/ehr343","article-title":"Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study","volume":"32","author":"Ekman","year":"2011","journal-title":"Eur Heart J"},{"key":"2026012114025080300_ehf213301-bib-0028","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/jama.2009.457","article-title":"Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial","volume":"301","author":"Flynn","year":"2009","journal-title":"JAMA"},{"key":"2026012114025080300_ehf213301-bib-0029","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.jacc.2012.06.054","article-title":"Cardiac resynchronization and quality of life in patients with minimally symptomatic heart failure","volume":"60","author":"Veazie","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026012114025080300_ehf213301-bib-0030","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003430","article-title":"Health-related quality of life outcomes in PARADIGM-HF","volume":"10","author":"Lewis","year":"2017","journal-title":"Circ Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13301","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13301","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/3\/1885\/65797968\/eschf_8_3_1885.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/3\/1885\/65797968\/eschf_8_3_1885.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:03:04Z","timestamp":1769022184000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/8\/3\/1885\/8363461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,30]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13301","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6]]},"published":{"date-parts":[[2021,3,30]]},"assertion":[{"value":"2021-01-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}